Safety of the PDE4 inhibitor roflumilast in COPD patients with chronic bronchitis

被引：0
|
作者：
Becker, J. C.
Pettenkofer, J.
Schmid-Wirlitsch, C. [1 ]
Gooss, A. [2 ]
机构：
[1] Nycomed Deutschland GmbH, Constance, DE, Germany
[2] Nycomed Pharma AG, Dubendorf, Switzerland
来源：
SWISS MEDICAL WEEKLY | 2010年 / 140卷 / 13-14期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：13S / 13S
页数：1
相关论文
共 50 条
  • [1] Safety of the PDE4 inhibitor roflumilast in COPD patients with chronic bronchitis
    Pohl, W.
    Sweilem, M.
    Voves, R.
    Jamnig, H.
    Moll-Schueler, I.
    Martinez, F. J.
    WIENER KLINISCHE WOCHENSCHRIFT, 2010, 122 (21-22) : A58 - A58
  • [2] Efficacy of the PDE4 inhibitor roflumilast in COPD patients with chronic bronchitis
    Pohl, W.
    Sweilem, M.
    Voves, R.
    Moll-Schueler, I.
    Riesenhuber, C.
    Calverly, P. M. A.
    WIENER KLINISCHE WOCHENSCHRIFT, 2010, 122 (21-22) : A57 - A58
  • [3] Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD
    -Martin, Eduardo Marquez
    Ruiz, Francisco Ortega
    Campano, Elena
    De la Horra, Carmen
    Varela, Jose Manuel
    Calderon, Enrique
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [4] Reduction in Systemic Inflammation by the PDE4 Inhibitor Roflumilast in Patients With COPD
    Marquez-martin, Eduardo
    Ortega, Francisco
    Campano, Elena
    de la Horra, Carmen
    Varela, Jose
    Calderon, Enrique
    CHEST, 2013, 144 (04)
  • [5] COPD: PDE4 inhibitor Roflumilast - from the symptom to the disease interference
    不详
    MEDIZINISCHE KLINIK, 2006, 101 (12) : XI - XII
  • [6] Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD
    Grootendorst, Diana C.
    Gauw, Stefanie A.
    Verhoosel, Renate M.
    Sterk, Peter J.
    Hospers, Jeannette J.
    Bredenbroeker, Dirk
    Bethke, Thomas D.
    Hiemstra, Pieter S.
    Rabe, Klaus F.
    THORAX, 2007, 62 (12) : 1081 - 1087
  • [7] The PDE4 inhibitor roflumilast provides additional clinical benefit in COPD patients treated with tiotropium
    Pohl, W.
    Voves, R.
    Sweilem, M.
    Moll-Schueler, I.
    Rabe, K. F.
    WIENER KLINISCHE WOCHENSCHRIFT, 2010, 122 (21-22) : A58 - A58
  • [8] The PDE4 inhibitor roflumilast provides additional clinical benefit in COPD patients receiving salmeterol
    Wuertz, J.
    Grillenberger, J.
    Hutter, C.
    Moll-Schueler, I.
    Riesenhuber, C.
    Izquierdo, J. L.
    WIENER KLINISCHE WOCHENSCHRIFT, 2010, 122 (21-22) : A58 - A59
  • [9] Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD
    Stephen I Rennard
    Peter MA Calverley
    Udo M Goehring
    Dirk Bredenbröker
    Fernando J Martinez
    Respiratory Research, 12
  • [10] The PDE4 inhibitor roflumilast provides additional clinical benefit in COPD patients receiving salmeterol
    Rolke, M.
    Schroeder-Babo, W.
    Faouzi, C.
    Gooss, A.
    Vogelmeier, C.
    Izquierdo, J. L.
    SWISS MEDICAL WEEKLY, 2010, 140 (13-14) : 13S - 13S
12345